189 related articles for article (PubMed ID: 37606037)
41. Current Prospects for Adrenocortical Carcinoma Pharmacotherapy.
Ławnicka H
Recent Pat Anticancer Drug Discov; 2023; 18(1):29-37. PubMed ID: 36482727
[TBL] [Abstract][Full Text] [Related]
42. In situ metabolomics of aldosterone-producing adenomas.
Murakami M; Rhayem Y; Kunzke T; Sun N; Feuchtinger A; Ludwig P; Strom TM; Gomez-Sanchez C; Knösel T; Kirchner T; Williams TA; Reincke M; Walch AK; Beuschlein F
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484828
[TBL] [Abstract][Full Text] [Related]
43. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
44. Molecular markers and targeted therapies for adrenocortical carcinoma.
Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
[TBL] [Abstract][Full Text] [Related]
45. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
Chabre O; Libé R; Assie G; Barreau O; Bertherat J; Bertagna X; Feige JJ; Cherradi N
Endocr Relat Cancer; 2013 Aug; 20(4):579-94. PubMed ID: 23756429
[TBL] [Abstract][Full Text] [Related]
46. Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma.
Liang J; Liu Z; Pei T; Xiao Y; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Yin X; Chen N; Wei X; Lu Y; Zhu Y
Dis Markers; 2020; 2020():5354825. PubMed ID: 31998416
[TBL] [Abstract][Full Text] [Related]
47. PERSONALIZED CARE OF PATIENTS WITH ADRENOCORTICAL CARCINOMA: A COMPREHENSIVE APPROACH.
Miller BS; Else T;
Endocr Pract; 2017 Jun; 23(6):705-715. PubMed ID: 28614035
[TBL] [Abstract][Full Text] [Related]
48. An Interesting Case of Hepatic Adrenocortical Carcinoma.
Permana H; Darmawan G; Ritonga E; Kusumawati M; Miftahurachman M; Soetedjo NN
Acta Med Indones; 2018 Jul; 50(3):257-259. PubMed ID: 30333277
[TBL] [Abstract][Full Text] [Related]
49. Expression of glucocorticoid receptor (GR) and clinical significance in adrenocortical carcinoma.
Wu K; Liu Z; Liang J; Zhang F; Zhang F; Wang Y; Lia T; Liu S; Zhu Y; Li X
Front Endocrinol (Lausanne); 2022; 13():903824. PubMed ID: 35992138
[TBL] [Abstract][Full Text] [Related]
50. Pediatric adrenocortical carcinoma.
Ilanchezhian M; Varghese DG; Glod JW; Reilly KM; Widemann BC; Pommier Y; Kaplan RN; Del Rivero J
Front Endocrinol (Lausanne); 2022; 13():961650. PubMed ID: 36387865
[TBL] [Abstract][Full Text] [Related]
51. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
[TBL] [Abstract][Full Text] [Related]
52. Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.
Tian X; Xu WH; Anwaier A; Wang HK; Wan FN; Cao DL; Luo WJ; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2021 Apr; 25(8):3898-3911. PubMed ID: 33626208
[TBL] [Abstract][Full Text] [Related]
53. 2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma.
Poli G; Ceni E; Armignacco R; Ercolino T; Canu L; Baroni G; Nesi G; Galli A; Mannelli M; Luconi M
Oncotarget; 2015 Mar; 6(8):5695-706. PubMed ID: 25691058
[TBL] [Abstract][Full Text] [Related]
54. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
[TBL] [Abstract][Full Text] [Related]
55. Assessment and management of advanced adrenocortical carcinoma using a precision oncology care model.
Elfiky AA; Krishnan Nair HK
Discov Med; 2016 Jan; 21(113):49-56. PubMed ID: 26896602
[TBL] [Abstract][Full Text] [Related]
56. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging: Diagnostic Pathways and Metabolites for Renal Tumor Entities.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Oncology; 2023; 101(2):126-133. PubMed ID: 36198279
[TBL] [Abstract][Full Text] [Related]
57. Spatial metabolomics principles and application to cancer research.
Planque M; Igelmann S; Ferreira Campos AM; Fendt SM
Curr Opin Chem Biol; 2023 Oct; 76():102362. PubMed ID: 37413787
[TBL] [Abstract][Full Text] [Related]
58. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
Luo Y; Chen Q; Lin J
Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
[TBL] [Abstract][Full Text] [Related]
59. PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target.
Demeure MJ; Coan KE; Grant CS; Komorowski RA; Stephan E; Sinari S; Mount D; Bussey KJ
Surgery; 2013 Dec; 154(6):1405-16; discussion 1416. PubMed ID: 24238056
[TBL] [Abstract][Full Text] [Related]
60. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
